Strategic Outsourcing: How CDMO Partnerships Are Tipping the Scales from Cost Efficiency to Supply Chain Resilience
Samsung Biologics’ James Choi outlined how global CDMOs are shifting from transactional vendors to integrated partners—embedding dual-source redundancy, digital traceability, and regulatory harmonisation to ensure biologics supply chains stay adaptive under geopolitical and market stress.
Global biopharmaceutical supply chains are under unprecedented strain. Geopolitical uncertainty, regulatory divergence, and escalating demands for speed and flexibility have transformed outsourcing from a cost-cutting exercise into a core resilience strategy. For many companies, the question is no longer whether to outsource, but how to do so intelligently—balancing reliability, agility, and long-term partnership value.
As James Choi, Executive Vice President and Chief Marketing Officer at Samsung Biologics, noted, the era of transactional outsourcing is ending. “In today’s environment, outsourcing has become a strategic lever for resilience,” he explained. “It’s about ensuring that your supply chain can adapt to change—whether that’s a regulatory shift, a supply disruption, or the need to accelerate development.”
From Monoclonals to Modalities: How ADCs and Bispecifics Are Shape the Biologics Growth Curve and CDMO Workings
Samsung Biologics projects that the global biologics market will grow from USD 355 billion in 2025 to USD 582 billion by 2031, reflecting a compound annual growth rate of 9%. This growth stems from expanding pipelines in ADCs, bispecific antibodies, and recombinant proteins. The surge reshapes CDMO strategy, shifting focus from a capacity race to diversified, platform-based development.
The biologics market grows not only through traditional monoclonal antibodies but also through next-generation modalities such as antibody–drug conjugates (ADCs) and multispecific antibodies. These modalities require specialized containment and high-precision manufacturing. Analysts expect them to contribute nearly 40% of new biologics pipeline growth by 2030, highlighting the importance of CDMOs that manage complex chemistries and scale up production with flexibility.
James Choi (featured), Executive Vice President and Chief Marketing Officer at Samsung Biologics, projects the global biologics market to grow from USD 355 billion in 2025 to USD 582 billion by 2031, reflecting a 9% annual growth rate. Image: GeneOnline
Building Redundancy and Agility Into the System
The pandemic years exposed how vulnerable global supply networks are. As biologics pipelines expand, companies must design systems that maintain continuity through redundancy and transparent coordination between drug developers and contract manufacturers. Choi emphasized that partnering with an established CDMO gives biopharma companies access to ready-built capacity, standardized quality systems, and global regulatory expertise.
This foundation of resilience depends on scale and standardization. The company’s fifth plant houses twelve 15 kL bioreactors and dual downstream lines, anchoring a global network with 784 kL of total capacity—the largest single-site biologics facility worldwide. Its 385 regulatory approvals across the FDA, EMA, and PMDA strengthen a “design once, approve globally” framework, allowing multiple facilities to operate under identical, validated systems.
In effect, this infrastructure transforms speed and reliability. Once one facility secures approval, another site can begin production immediately, reducing delays and ensuring consistent output across regions. This model converts manufacturing from a fragmented, site-specific process into a harmonized global network designed for agility and regulatory alignment. Consequently, companies now prioritize partnership over expansion. Rather than spend years constructing new facilities, biopharma firms work with integrated partners that already run validated plants and hold strong compliance records with international regulators. “The value isn’t only in physical capacity,” Choi said. “It’s in the ability to pivot quickly, to transfer technology seamlessly, and to maintain consistent quality across different geographies.”
Ultimately, this evolution redefines resilience. Instead of reacting to disruption, companies now engineer flexibility, quality, and continuity into their supply networks from the start. The result is a system where resilience functions not as an emergency response, but as a built-in design principle that sustains global biologics production under any conditions.
Evolving From Vendor to Strategic Partner
The relationship between drug sponsors and manufacturing partners has also evolved. Today’s CDMOs are expected to play a cross-functional role—bridging R&D, process development, and commercial operations. This evolution reflects the growing complexity of biologics, where tech transfer and scale-up are no longer linear but concurrent processes.
“Resilience requires integration,” Choi observed. “We’re seeing more sponsors involve their CDMO partners much earlier in development, even during candidate selection. That collaboration enables better design for manufacturability and ultimately reduces time to market.”
To enable this shift, leading CDMOs have adopted digital platforms for real-time visibility and standardised process controls across multiple plants. These systems allow clients to track progress, quality metrics, and supply status instantly—supporting both transparency and trust.
Samsung Biologics’s “co-located operations” model compresses the traditional drug-substance–to–drug-product transition from 81 days to 32, reducing redundant analytical work and eliminating inter-site transport risk. The company’s standardized Exellens™ platform further enables dual-source manufacturing, allowing seamless production transfer between facilities in the event of supply disruptions.
Navigating Regulatory Fragmentation
As supply chains globalise, regulatory alignment remains one of the toughest challenges. Divergent documentation standards and regional inspection practices can slow product approvals and complicate global launches. Here again, experience matters. CDMOs that have obtained hundreds of regulatory approvals across the United States, Europe, and Asia bring not only compliance assurance but institutional memory of what each market requires.
According to Choi, this cumulative experience can be decisive. “When you’re dealing with agencies from multiple jurisdictions, prior approval history is a huge asset. It means we understand what data is needed, what the common pitfalls are, and how to ensure readiness across different authorities.”
Structuring Outsourcing for Long-Term Resilience
For emerging biopharma firms, outsourcing strategy can feel daunting. Choi offered a pragmatic framework that mirrors how established players approach CDMO partnerships:
- Define your critical path. Map which elements of development and manufacturing most influence your timeline or risk exposure.
- Select partners for complementarity, not convenience. The right CDMO should extend your internal capabilities—not merely duplicate them.
- Plan for dual sourcing early. Redundant supply options should be embedded in the program from the start, not after a disruption occurs.
- Integrate communication systems. Real-time information flow between sponsor and CDMO is as vital as the physical production line.
- View outsourcing as continuous co-development. The best partnerships evolve dynamically, aligning incentives and knowledge sharing over the long term.
From Resilience to Reliability by Design
Ultimately, Choi’s message signals a clear industry shift. As biologics pipelines diversify and global risks rise, companies now equate supply resilience with design excellence. Future-ready CDMOs are not just expanding capacity—they are actively co-architecting sustainable manufacturing networks where speed, quality, and continuity coexist by design, not by contingency.
Moreover, Choi emphasized that true resilience depends on foresight, not reaction. “Resilience isn’t about reacting faster,” he said. “It’s about designing systems that don’t break under stress. And that’s what strategic outsourcing now means in biopharma.”
Consequently, the impact extends far beyond Samsung Biologics. CDMOs worldwide are standardizing compliance, enhancing digital traceability, and embedding dual-source redundancy into global operations. Together, these advances are redefining how resilience is measured—and transforming what once began as a cost-efficiency model into the strategic backbone of the post-pandemic biopharma economy.
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Indian Generics Gain Ground in China as the Global Procurement Landscape Demands a New Industrial Model
2025-11-13
A New Order in APAC Biosimilar Market: From Manufacturing Powerhouses to Value-Driven Innovators
2025-11-13
South Korea’s Samsung Biologics Completes Spin-Off of Bioepis to Refocus on Global CDMO Strategy
2025-11-06
